|
Pt
|
Age
|
Cancer
|
Stage on enrollment
|
# of cycles
|
Off-study reason
|
PFS#(ms)
|
OS* (ms)
|
Immune response
|
|---|
|
Proliferative assay
|
Elispot
|
|---|
| | | | | | | | |
Pre-vaccine
|
Post-vaccine
|
Pre-vaccine
|
Post-vaccine
|
|---|
|
1A
|
56
|
Colon
|
IV
|
2
|
PD
|
0.5
|
5.5
|
ND
|
|
2A
|
57
|
Colon
|
IV
|
3
|
PD
|
3.9
|
16.8
|
NA
|
-
|
-
|
|
3A
|
62
|
Colon
|
IV
|
3
|
PD
|
5.8
|
21.5
|
-
|
-
|
-
|
-
|
|
4A
|
50
|
Pancreatic
|
IV
|
3
|
PD
|
3.6
|
6.2
|
-
|
-
|
-
|
-
|
|
5A
|
60
|
Lung
|
IV
|
1
|
PD
|
1
|
2.8
|
ND
|
|
6A
|
59
|
Colon
|
IV
|
3
|
PD
|
3.5
|
8.9
|
NA
|
|
7A
|
52
|
Colon
|
NED
|
11
|
Completed
|
129+
|
129+
|
-
|
+
|
-
|
+
|
|
8A
|
68
|
Lung
|
IV
|
3
|
PD
|
3.6
|
13.1
|
-
|
-
|
-
|
-
|
|
9A
|
56
|
Colon
|
NED
|
10
|
PPS
|
18.8
|
37.2
|
-
|
+
|
-
|
+
|
|
10A
|
63
|
Colon
|
IV
|
3
|
PD
|
3.3
|
19.9
|
-
|
-
|
-
|
-
|
|
11A
|
42
|
Pancreatic
|
NED
|
6
|
PD
|
7.5
|
24.1
|
-
|
-
|
-
|
-
|
|
12A
|
39
|
Colon
|
NED
|
3
|
PD
|
6.2
|
23
|
-
|
-
|
-
|
-
|
|
13A
|
67
|
Colon
|
IV
|
3
|
PD
|
3.5
|
4.8
|
-
|
+
|
+
|
+
|
|
14A
|
51
|
Colon
|
NED
|
3
|
PD
|
7.1
|
41.3
|
-
|
-
|
-
|
-
|
|
15A
|
60
|
Pancreatic
|
IV
|
3
|
PPS/Lost to follow-up
|
2.7+
|
5.3
|
NA
|
-
|
-
|
|
16A
|
61
|
Colon
|
IV
|
3
|
PD
|
3.6
|
17.3
|
-
|
+
|
-
|
-
|
-
#Progression free survival was calculated as time from the date the consent was signed until evidence of disease progression or last follow-up without progression (+). *Overall Survival was calculated as time from consent date until death or last follow-up (+). ND, not done because patient received 2 or less vaccines; NA, sample not available. Immune response was marked as negative (-) or positive (+) as described in the manuscript.
-
Abbreviations: NED No Evidence of Disease, PD Progression of Disease, PPS Poor Performance Status, SD Stable Disease, PFS Progression Free Survival, OS Overall Survival, ms Months.
